GlassScriptPhysician profile
Weldon Gaston James
NPI 1053499970
$1,620.79
in general payments reported to CMS, 2019-2025
29 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $118 · 2023: $47.56 · 2024: $554 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Consulting Fee: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.00 |
| Consulting Fee | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $239.79 | 2021-2022 | |
| Viiv Healthcare Company | $137.69 | 2024 | Apretude, Dovato |
| Astrazeneca Pharmaceuticals LP | $133.73 | 2024 | Breztri, Farxiga |
| Idorsia Pharmaceuticals US INC | $125.00 | 2024 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $120.00 | 2025 | |
| Novo Nordisk INC | $109.83 | 2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $70.22 | 2025 | |
| Abbvie INC. | $65.03 | 2024 | |
| Dexcom, INC. | $57.52 | 2024-2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $49.14 | 2024-2025 | Injectafer |
| Amgen INC. | $47.72 | 2025 | Repatha, Otezla |
| Shield Therapeutics INC | $45.39 | 2024-2025 | |
| Lilly USA, LLC | $41.82 | 2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $40.04 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $34.16 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $32.03 | 2025 | Nuzyra |
| Alkermes, INC. | $28.76 | 2023 | Aristada, Lybalvi |
| Corcept Therapeutics | $26.69 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.31 | 2025 | Caplyta |
| Viatris Specialty LLC | $24.06 | 2025 | Yupelri |
| Gilead Sciences, INC. | $22.66 | 2025 | |
| Tolmar, INC. | $21.57 | 2025 | Jatenzo |
| Mannkind Corporation | $19.01 | 2025 | |
| Baxter Healthcare | $18.80 | 2023 | Hillrom - Retinavue 700 Imager |
| Phathom Pharmaceuticals, INC. | $18.62 | 2025 | Voquezna |
| Intra-Sana Laboratories | $17.26 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Pfizer INC. | $16.24 | 2025 | |
| Antares Pharma, INC. | $15.87 | 2024 | Xyosted |
| Phadia US INC. | $15.83 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weldon James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.